Tuesday, October 25, 2016 9:37:02 AM
$AERI <====> $CYCC
https://www.linkedin.com/jobs/view/223453164
Job description
Applying its core strength in cell cycle biology, Cyclacel is advancing a pipeline of orally available, small molecule, investigational drugs designed to stop uncontrolled cell division. Sapacitabine, our lead drug candidate, is being evaluated in the SEAMLESS pivotal Phase 3 trial in elderly patients with acute myeloid leukemia under a Special Protocol Assessment agreement with the US Food and Drug Administration. For more information on our investigational drug programs and clinical trials, please go to the Research & Development tab above.
Recent CYCC News
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 04/01/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/07/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit • GlobeNewswire Inc. • 03/06/2024 02:15:00 PM
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 01/30/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Cyclacel Pharmaceuticals Announces Reverse Stock Split • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/28/2023 10:15:00 PM
- Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/03/2023 01:15:00 PM
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/11/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results • GlobeNewswire Inc. • 05/04/2023 01:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit • GlobeNewswire Inc. • 05/03/2023 01:15:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM